Supplementation with Beta-Hydroxy-beta-methylbutyrate Impacts Glucose Homeostasis and Increases Liver Size in Trained Mice.

beta-hydroxy-beta-methyl butyrate (HMB) is a bioactive metabolite aerivea from the amino acid leucine, usually applied for muscle mass increase during physical training, as well as for muscle mass maintenance in debilitating chronic diseases. The hypothesis of the present study is that HMB is a safe supplement for muscle mass gain by strength training. Based on this, the objective was to measure changes in body composition, glucose homeostasis and hepatic metabolism of HMB supplemented mice during strength training. Two of four groups of male mice (n = 6/group) underwent an 8-week training period session (climbing stairs) with or without HMB supplementation (190 mg/kgBW per day). We observed lower body mass gain (4.9 +/- 0.43% versus 1.2 +/- 0.43, p < 0.001) and increased liver mass (40.9 +/- 0.9 mg/gBW versus 44.8 +/- 1.3, p < 0.001) in the supplemented trained group compared with the non-supplemented groups. The supplemented trained group had an increase in relative adipose tissue mass (12.4 +/- 0.63 mg/gBW versus 16.1 +/- 0.88, P < 0.01) compared to the non-supplemented untrained group, and an increase in fasting blood glucose (111 +/- 4.58 mg/dL versus 122 +/- 3.70, P < 0.05) and insulin resistance (3.79 +/- 0.19 % glucose decay/min versus 2.45 +/- 0.28, P < 0.05) comparing with non-supplemented trained group. Adaptive heart hypertrophy was observed only in the non-supplemented trained group (4.82 +/- 0.05 mg/gBW versus 5.12 +/- 0.13, P < 0.05). There was a higher hepatic insulin-like growth factor-1 expression (P = 0.002) in supplemented untrained comparing with non-supplemented untrained group. Gene expression of gluconeogenesis regulatory factors was increased by training and reduced by HMB supplementation. These results confirm that HMB supplementation associated with intensive training protocol drives changes in glucose homeostasis and liver metabolism in mice.